Fri, Aug 22, 2014, 7:20 AM EDT - U.S. Markets open in 2 hrs 10 mins

Recent

% | $
Quotes you view appear here for quick access.

BIOLASE, Inc. Message Board

  • lookingforatenbagger lookingforatenbagger Jan 31, 2013 1:18 PM Flag

    Freddie's leadership role in Biolase

    Simon wrote the following in another thread;
    "Hi LFTB,
    You are misleading in your statement about Pinatelli. The management went against his wishes when they brought in Henry Schein (HS) as an exclusive distributor. Which tells me that apparently Pignatelli was not in control. The initial results from HS was not as good as you describe and how "well" they did was based on the previous sales momentum BIOL had developed under Pignatelli's system. Pignatelli had to have a coup and take over the reigns in order to get BIOL sales going again. That process has just been put into motion and sales are starting to gather momentum again. Also the small stock dividends he is distributing to shareholders is not in the least diluting the shareholders. I have the same percentage of the company now as I had previous to the stock dividend. These stock dividends are actually minor stock splits. That is not a bad deal. As I said before, let's compare notes at the end of the year!

    Best Regards,

    Simon"

    There seems to be a misunderstanding. Simon claims "management went against his [Freddie's] wishes when they brought in Henry Schein (HS) as an exclusive distributor." Although Freddie claims this now, I don't beleive this to be true. In fact, I believe it was one of the reasons Jeff Jones was replaced. Jones had been pushed aside to bring in Bob Grant. Grant was opposed to the Schein move and FREDDIE pushed Grant out and brought Jones back in 5/06 to implement the change. Schein started in 8/06. In 11/07 FREDDIE pushed Jones out and took over direct control because FREDDIE thought Jones kept to many Biolase salemen and wanted Schein to handle MORE marketing. One can ask Jeff Jones about it.

    If you look at the numbers, you'll see just how BAD that move was. Once Schein lost teh Biolase sale back up things went down hill fast. Don't forget, the sales numbers in the Schein years need to have 10% to 15% added to them to make an apples to apples comparison to other years.

    Revenue History (Millions):
    Year…Q1…Q2…Q3…Q4..Total
    -----------------------------------
    2004…14…15….12…19…61
    2005…17…15….12…19…62
    2006…17…16….17…19…70
    2007…15…17….12…24…67 [Schein 77]
    2008…19…18…15…12…64 [Schein 74]
    2009…06…14…12…10…43 [Schein 49]
    2010…04…06…06…10…26
    2011….11….12….13….13…49
    2012….12….13*….14….18(e)…57

    Does anyone remember how Freddie bragged about being able to bring in sales and profit those two months he was in direct control?

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • All experts here: debate Patents

      Did Biolase Management ever claim that no one can enter dental laser markets without infringing on their core patents?
      Yes or no?

      And Management should update on Patent law suits and any royalty that they receive from competition.

      RISK disclosure: We face competition from other companies, many of which have substantially greater resources than we do. If we do not successfully develop and commercialize enhanced or new products that remain competitive with products or alternative technologies developed by others, we could lose revenue opportunities and customers and our ability to grow our business would be impaired.
      A number of competitors have substantially greater capital resources, larger customer bases,larger technical, sales and marketing forces and have established stronger reputations with target customers than ours. We compete with a number of domestic and foreign companies that market traditional dental products, such as dental drills, as well as companies that market laser technologies in the dental and medical markets. The marketplace is highly fragmented and very competitive.


      And make your case here folks; Let retail investors have real hard facts too..............

      • 1 Reply to singhlion2001
      • 9:02AM Biolase receives FDA clearance for its 940nm Diolase 10 diode soft tissue laser for a broad spectrum of medical procedures (BIOL) 2.83 : Co announces the FDA has cleared the 940nm Diolase 10 diode soft tissue laser for use in 19 additional medical markets including: ear, nose and throat, oral surgery, arthroscopy, gastroenterology, general surgery, dermatology, plastic surgery, podiatry, GI/GU, gynecology, neurosurgery, ophthalmology, pulmonary surgery, cardiac surgery, thoracic surgery, urology, dermatology, aesthetics, and vascular surgery. This FDA clearance includes over 80 different procedures.

        What is new in this news?LOL

        Great trading and dumping today...smart money locking the gains

    • And why rehash thr past in such detail "looking" and what end you gutless shill of an ex employee? The here and now is Freddie as u say has rebuilt a company now growing at least 15-20% with positive CF and EPS and is self sustaining.. The last 2 years that is contrary to all your lies here and bashing........you will be exposed and yahoo will reveal your true identity so.......and whether you or others are behind the stk manipulation running rampant thru EDGX ie knight by pushing shrs down at every spike we will see but will get exposed too thru regulators........i see your games and so do others and wont work as fundammental forces take over....they will grow every qrt this year at least 15% and no one will care about your rants....

      • 2 Replies to breakem1
      • How come these folks still in business and claim a superior product to Biolase now?

        Syneron Dental Lasers

        Dr. Reyhanian Avi , DDS / Private clinic ,Netanya Israel
        I’ve been using lasers in my clinic since 2002. The most important & dominant laser in my clinic is the LiteTouch™ Er: YAG laser (2940nm). LiteTouch™ is the main tool used in my clinic, for oral surgery procedures among others.

        LiteTouch™ has a wide range of advantages vs. others lasers:
        Due to his Laser-in-the-Handpiece technology (no fiber), its powerful laser output and the unique ergonomic applicator, allow me to conduct fast and precise procedures, helping me to achieve patient’s satisfaction.

        LiteTouch™ is the smallest Er:YAG laser in the world and can fit anywhere in my clinic. One should not underestimate that maintenance of other Er:YAG lasers is expensive due to fiber related issues. LiteTouch™’s high reliability saves unnecessary maintenance costs and increases my clinic’s revenues.

        As the first doctor in the world that has LiteTouch™ in his hands & after experiencing many other lasers, I immediately "fell in love" with this device.

        LiteTouch™ had become an integral and essential part of clinic, and indispensable in my professional career.

        I recommend my colleagues to have LiteTouch™, as LiteTouch™ named advantages contributed to boost my clinic’s reputation and revenues.

        Today I’m a very proud luminary doctor of LiteTouch for Syneron Dental Lasers, a breakthrough company that invests a lot in clinical training's, spreading knowledge and couching the next generation dentists.

      • O'dear breakm1

        I love to do due diligence on so called disruptive technologies and their mass adoption curves and so far have accurately predicted success and demise of many technologies based on future profits sustainability.It takes very clever approach to grab quick market share with new disruptions. Dental laser disruptive technology and adoption after 20 years still at snail pace and why?

        Can you enlighten us my dear Breakem1?

        Regards

        Lion

    • Freddie is crazy as he thinks he can conquer what? with water lase technology?

      DENTAL LASERS still have not brought in profits and he is spreading his wings to ophthalmology. field with same high Drama with water lase:.........

      20 years Dental laser did not turn a profit and how many decades experiments will be at Occulase??LOL

      My cousin is an Eye Surgeon and I discussed Occulase technology and listed procedures and he had a great laugh

      I have stated here before that this distribution business model required a very big cash infusion and without immediate cash infusion , no way this can gain any major market penetration ....

      DISTRIBUTION 7 MARKETING new technology is not a child's play ground, it requires Great Marketing brains with very deep practical experience

      This is a story stock and Freddie loves telling long stories to Share holders: LOL

      ===============
      Presbyopia

      By Gretchyn Bailey

      Presbyopia treatment FAQ
      Presbyopia usually occurs beginning at around age 40, when people experience blurred near vision when reading, sewing or working at the computer.

      You can't escape presbyopia, even if you've never had a vision problem before. Even people who are nearsighted will notice that their near vision blurs when they wear their usual eyeglasses or contact lenses to correct distance vision.

      Presbyopia is widespread in the United States. According to U.S. Census Bureau data, over 135 million Americans were age 40 and older in 2008, and the country is growing older: The median age reached 36.8 in 2008, up 1.5 years since 2000. This growing number of older citizens generates a huge demand for eyewear, contact lenses and surgery that can help presbyopes deal with their failing near vision.

      More than a billion people in the world were presbyopic as of 2005, according to the World Health Organization, and 517 million of these did not have adequate correction with eyeglasses. In developing countries, glasses are available in urban areas, but in rural regions they are unavailable or expensive. This is unfortunate, because good near vision is important for literacy and for performing closeup work.

      Presbyopia Symptoms and Signs

      When people develop presbyopia, they find they need to hold books, magazines, newspapers, menus and other reading materials at arm's length in order to focus properly. When they perform near work, such as embroidery or handwriting, they may develop headaches, eye strain or feel fatigued.

      What Causes Presbyopia?

      Presbyopia is caused by an age-related process. This differs from astigmatism, nearsightedness and farsightedness, which are related to the shape of the eyeball and are caused by genetic and environmental factors. Presbyopia generally is believed to stem from a gradual thickening and loss of flexibility of the natural lens inside your eye.

      These age-related changes occur within the proteins in the lens, making the lens harder and less elastic over time. Age-related changes also take place in the muscle fibers surrounding the lens. With less elasticity, the eye has a harder time focusing up close. Other, less popular theories exist as well.

      Presbyopia Treatment: Eyewear

      Eyeglasses with bifocal or progressive addition lenses (PALs) are the most common correction for presbyopia. Bifocal means two points of focus: the main part of the spectacle lens contains a prescription for distance vision, while the lower portion of the lens holds the stronger near prescription for close work.

      The eye's lens stiffens with age, so it is less able to focus when you view something up close. (Image: Varilux)
      Progressive addition lenses are similar to bifocal lenses, but they offer a more gradual visual transition between the two prescriptions, with no visible line between them.

      Reading glasses are another choice. Unlike bifocals and PALs, which most people wear all day, reading glasses typically are worn just during close work.

      If you wear contact lenses, your eye doctor can prescribe reading glasses that you wear while your contacts are in. You may purchase readers over-the-counter at a retail store, or you can get higher-quality versions prescribed by your eye doctor.

      Presbyopes also can opt for multifocal contact lenses, available in gas permeable or soft lens materials. Another type of contact lens correction for presbyopia is monovision, in which one eye wears a distance prescription, and the other wears a prescription for near vision. The brain learns to favor one eye or the other for different tasks. But while some people are delighted with this solution, others complain of reduced visual acuity and some loss of depth perception with monovision.

      Because the human lens continues to change as you grow older, your presbyopic prescription will need to be increased over time as well. You can expect your eye care practitioner to prescribe a stronger correction for near work as you need it.

      Presbyopia Treatment: Surgery

      Surgical options to treat presbyopia also are available. One example is Refractec Inc.'s conductive keratoplasty or NearVision CK treatment, which uses radio waves to create more curvature in the cornea for a higher "plus" prescription to improve near vision. The procedure is performed on one eye only for a monovision correction.

      Presbyopia News
      Why Do Women Need Reading
      Glasses Earlier Than Men?
      July 2012 — Are differences in eye anatomy and focusing ability responsible for women needing presbyopia correction earlier than men?

      According to a new analysis of presbyopia prevalence studies, this is not the reason. Instead, it has to do with arm length or preferred reading distance.
      On average, women's arms are shorter than men's, and when it becomes more and more difficult to read at arm's length, women must turn to presbyopia correction such as reading glasses sooner. Accordingly, they also need higher-powered reading glasses or bifocals than men of the same age.
      In developing countries, this is a big issue since reading glasses are not widely available. Without them, it is very challenging for women who do closeup work to continue to make a living as they age.
      A report of the study appeared in Investigative Ophthalmology & Visual Science in May.

      Studies have shown that NearVision CK effectively treats presbyopia, but the correction is temporary and diminishes over time.

      PresbyLASIK is a new presbyopia-correcting surgery now undergoing U.S. clinical trials. This innovative procedure uses an excimer laser to create a multifocal ablation directly on the eye's clear front surface (cornea). This enables vision at multiple distances.

      LASIK also can be used to create monovision, in which one eye is corrected for near vision while the other eye is stronger for distance vision.

      A highly experimental treatment being studied is the injection of an elastic gel into the capsular bag, the structure in the eye that contains the natural lens. In theory, the gel would replace the natural lens and serve as a new, more elastic lens.

      Experiments also have centered on laser treatment of the eye's hardened lens to increase its flexibility and thereby improve focus.

      With the recent introduction of presbyopia-correcting intraocular lenses, some people undergoing cataract surgery may be able to achieve clear vision at all distances.

      Also, an elective procedure known as refractive lens exchange may enable you to replace your eye's clear but inflexible natural lens with an artificial presbyopia-correcting lens for multifocal vision.

      • 1 Reply to singhlion2001
      • New Laser Eye Surgery Helps "Presbyopic" Patients
        A new eye surgery technique has proven excellent at eliminating a common vision condition affecting most middle-aged and elderly people, a recent study showed. The condition, known as presbyopia , starts to appear around age 40 and causes blurring in one’s near vision as the eye’s natural lens gradually loses its flexibility. A nearsighted person with presbyopia can’t see up close with his usual glasses or contact lenses, but is able to see nearby things clearly without them.

        The new presbyopia treatment, which is undergoing clinical trials in the United States but which has been used for several years in other countries, is called presbyLASIK or multifocal LASIK. The term multifocal is used because the procedure addresses the eyes’ need for multiple focuses in terms of near, intermediate and distance vision.

        In a study led by Robert L. Epstein, of the Mercy Center for Corrective Eye Surgery, in McHenry, Ill., 92 percent of middle-aged patients were freed of the need for glasses. In follow-up on the participants, who had an average age of 53 and who came to the study wearing bifocals and reading glasses, the beneficial result was shown to last beyond two years.

        Presbyopia is usually corrected with multifocal eyeglasses or contact lenses, which are made with at least three “zones” of power for enhancing sight at all distances. In presbyLASIK, which can also help patients who have had cataract surgery or whose eyes are otherwise inappropriate for LASIK surgery, a laser sculpts three corrective vision zones into the surface of the eye – for far, near and intermediate vision. The patient’s brain then chooses which zone to use for the vision that’s required for a particular task.

        In each zone, the sculpted cornea bends light differently, allowing presbyopia sufferers to regain good vision at any distance. This is just how multifocal contact lenses work – but, since they rest on the eye’s surface, they can shift, causing sight distortions.

        To date, the Food and Drug Administration has approved only one LASIK procedure for correcting presbyopia. It provides so-called monovision, in which one eye is operated on to improve distance vision, and the other for better near vision. But many people find it difficult to adapt to this arrangement, which can cause problems such as loss of depth perception.

 
BIOL
2.14-0.05(-2.28%)Aug 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.